Advertisement Immunotech completes negotiations with Uldic to market potential Ebola treatment in Africa - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Immunotech completes negotiations with Uldic to market potential Ebola treatment in Africa

Immunotech Laboratories has completed negotiations with Zimbabwe-based Uldic Investment (Uldic) to pursue the development of market opportunities related to potential treatment of the deadly Ebola virus in Sub-Saharan West Africa.

Ebola virus virion

The US-based company has also agreed to carry out human clinical trials using its HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1) in the region.

With the establishment of an African operation, the firm intends to bring a therapy based on the patented Inactivated Pepsin Fraction (IPF) protein developed for infectious diseases such as HIV/AIDS, Hepatitis C and the Ebola virus.

Currently, approved experimental treatments are permitted in parts of Africa and with the Ebola outbreak, the company intends that it can market its treatment for infectious diseases through its new agreement with Uldic.

ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), a platform technology that can be used to facilitate a broad range of applications.

IPF is free from neurological, gastrointestinal and hematological side effects seen in the existing anti-retrovirals.

According to the company, the immune system has components that bind and present antigens to cells that are capable of starting a response to those antigens.

The company has isolated IPF which is the most extensively studied CD 56 ligand to date.

The compounds has the ability to stimulate human NKT-cell lines, secretion of key cytokines such as IFN- IL 2 and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor.


Image: Ebola virus virion. Photo: courtesy of CDC/Cynthia Goldsmith.